Work

Pharmacological profile, phase I metabolism, and excretion time profile of the new synthetic cathinone 3,4‐Pr‐PipVP

Year: 2023

Type: article

Abstract: 1‐(2,3‐Dihydro‐1H‐inden‐5‐yl)‐2‐(piperidin‐1‐yl)pentan‐1‐one (3,4‐Pr‐PipVP), a novel synthetic cathinone (SCat), was first identified in 2022 in Germany. The product was marketed as 1‐(bicyclo[4.2.0]octa‐1,3,5‐trien‐3‐yl)‐2‐(pyrrolidin‐1‐yl)pentan‐1‐one (3,4‐EtPV), a substance not covered by the German New Psychoactive Substances Act (NpSG). Although originally intended to be an exploratory new synthetic cathinone containing the novel bicyclo[4.2.0]octatrienyl function, the compound was subsequently confirmed to contain an indanyl ring system scheduled under generic legislation like the NpSG. However, it is one of only a few marketed SCats carrying a piperidine ring. Inhibition experiments involving norepinephrine, dopamine, and serotonin transporters showed that 3,4‐Pr‐PipVP was a low potency blocker at all three monoamine transporters compared to related substances such as MDPV. Additionally, pharmacokinetic data were collected from pooled human liver microsomes incubations and from the analysis of authentic urine samples received after oral administration of 5 mg 3,4‐Pr‐PipVP hydrochloride. Phase I metabolites were tentatively identified in vitro and in vivo using liquid chromatography−time‐of‐flight mass spectrometry. Main metabolites were formed by metabolic reduction of the carbonyl function with and without additional hydroxylations at the propylene bridge of the molecule. Keto‐reduced H2–3,4‐Pr‐PipVP and H2‐piperidine‐OH‐3,4‐Pr‐PipVP as well as aryl‐OH‐3,4‐Pr‐PipVP, and indanyl‐OH‐piperidine‐OH‐3,4‐Pr‐PipVP are suggested as most suitable biomarkers for the detection of 3,4‐Pr‐PipVP since they were detected for much longer than the parent compound. 3,4‐Pr‐PipVP could be detected for up to 21 h whereas its metabolites were detectable for up to about 4 days.

Source: Drug Testing and Analysis

DOI: 10.1002/dta.3538

Authors: Hannes Max Schwelm, Mattias Persson, Benedikt Pulver, Max Vincent Huß, Henrik Gréen, Volker Auwärter

Institutions: University of Freiburg, University Medical Center Freiburg, Swedish National Board of Forensic Medicine, Linköping University

Language: English

Topic: Forensic Toxicology and Drug Analysis

Subfield: Toxicology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,840